Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Tafenoquine for Malaria Chemosuppression in Kenya
NCT02491606Phase 2Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- May 1997
- Primary completion
- Sep 1997
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of tafenoquine in malaria (4 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoint: Prophylactic outcome at 13 weeks. Started May 1997; status: completed.
02
Drugs
tafenoquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02491606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02491606.